

## GENERAL INFORMATION

The Conference will be accredited for N. 50 Italian following professionals:

- **Medical Doctor:** Allergology and Clinical Immunology, Clinical Pathology, Dermatology, Ematology, General Surgery, Medical Genetics, Nephrology, Nuclear Medicine, Oncology, Pathological Anatomy, Plastic Surgery, Radiodiagnostic and Radiotherapeutic, Respiratory Medicine, Thoracic Surgery, Urology
- **Biologists**
- **Hospital pharmacist**

**ECM N° 226000 - CREDITS: 4**

*Acquisition of Credits under current Age.n.a.s legislation*

## FACULTY:

PAOLO ANTONIO ASCIERTO	NAPOLI
ANTONIO AVALLONE	NAPOLI
ALFREDO BUDILLON	NAPOLI
GIACOMO CARTENÌ	NAPOLI
FORTUNATO CIARDIELLO	NAPOLI
SABINO DE PLACIDO	NAPOLI
PAOLO MAIONE	AVELLINO
VINCENZO MONTESARCHIO	NAPOLI
ALESSANDRO MORABITO	NAPOLI
STEFANO PEPE	SALERNO

Pre-registrations exclusively through the website [www.strategieonweb.it](http://www.strategieonweb.it)

*With unconditional restricted grant*

Major Sponsor



Bristol-Myers Squibb


AstraZeneca



PROVIDER AND ORGANIZING SECRETARIAT  
STRATEGIE S.R.L.

VIA PIAVE 110/7 • 65122 PESCARA  
TEL 085 74143 • FAX 085 378220 • CELL. 392 6407122

[INFO@STRATEGIEONWEB.IT](mailto:INFO@STRATEGIEONWEB.IT)  
[WWW.STRATEGIEONWEB.IT](http://WWW.STRATEGIEONWEB.IT)



# Focus on Cancer and Immuno-Oncology

## NAPLES 15th JUNE 2018

**Presidents** Sabino De Placido & Fortunato Ciardiello  
**Coordinator** Giacomo Cartenì

## ROYAL CONTINENTAL

Via Partenope, 38/44

# RATIONALE

Today the immuno-oncology (I-O) represents a revolution in the field of oncology. The checkpoints inhibitors (anti-CTLA4, anti-PD-1, etc.), are able to kill cancer cells indirectly, through the interaction with the immune system cells.

The characteristics of adaptability and memory of the immune-system make it able to reach longterm survival (more than 10 years). For this reason, I-O became the fourth pillars in the treatment of cancer together surgery, radiotherapy, and chemotherapy.

After the excellent results reached in different type of cancers, I-O is exploring a wide range of new molecules and possible combinations or sequencing, in order to increase the number of patients with a long-term benefit.

The intent of this course , with contributions from Società Campana di Immunoncologia (SCITO) is to offer a general educational overview about the topics described.

# PROGRAM

> 13:00/13:30	Welcome
> 14:00	Introduction <b>Sabino De Placido &amp; Fortunato Ciardiello</b>
>14:30	<b>Chair Sabino De Placido</b> <b>Speaker Paolo A. Ascierto</b> News in Melanoma
>15:00	<b>Chair Paolo Maione</b> <b>Speaker Alessandro Morabito</b> News in K Lung
> 15:40	<b>Chair Sabino De Placido</b> <b>Speaker Giacomo Cartenì</b> News in K Kidney
> 16:10	<b>Chair Stefano Pepe</b> <b>Speaker Vincenzo Montesarchio</b> News about immunotherapy in the other cancers
> 16:40	<b>Chair Alfredo Budillon</b> <b>Speaker Antonio Avallone</b> News in Colo-Rectal Cancer
> 17:10	<i>Break</i>
> 17:20	<b>Chair Sabino De Placido &amp; Fortunato Ciardiello</b> Discussion between Faculty and Participants
> 18:10	Closing Remarks - Test ECM